Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: a systems biology approach.
Fonseca DLM, Filgueiras IS, Marques AHC, Vojdani E, Halpert G, Ostrinski Y, Baiocchi GC, Plaça DR, Freire PP, Pour SZ, Moll G, Catar R, Lavi YB, Silverberg JI, Zimmerman J, Cabral-Miranda G, Carvalho RF, Khan TA, Heidecke H, Dalmolin RJS, Luchessi AD, Ochs HD, Schimke LF, Amital H, Riemekasten G, Zyskind I, Rosenberg AZ, Vojdani A, Shoenfeld Y, Cabral-Marques O. Fonseca DLM, et al. Among authors: silverberg ji. NPJ Aging. 2023 Aug 24;9(1):21. doi: 10.1038/s41514-023-00118-0. NPJ Aging. 2023. PMID: 37620330 Free PMC article.
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry.
Haft MA, Knapp KD, Claxton A, Munoz B, Crawford JM, Balu S, Kim Y, Schneider S, Eichenfield DZ, Silverberg JI, Eichenfield LF, Bagel J, Rhoads JLW, Paller AS. Haft MA, et al. Among authors: silverberg ji. Curr Med Res Opin. 2024 Dec;40(12):2057-2066. doi: 10.1080/03007995.2024.2427883. Epub 2024 Dec 2. Curr Med Res Opin. 2024. PMID: 39623757
Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany.
Durno N, Arija P, Pantiri K, Heisen M, Boeri M, Paris J, Jack K, Chambenoit O, Subramanian R, Puelles J, Stolk E, van Hout B, Silverberg JI. Durno N, et al. Among authors: silverberg ji. J Dermatolog Treat. 2024 Dec;35(1):2417966. doi: 10.1080/09546634.2024.2417966. Epub 2024 Oct 27. J Dermatolog Treat. 2024. PMID: 39462516 Free article.
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.
Silverberg JI, Rosmarin D, Chovatiya R, Bieber T, Schleicher S, Beck L, Gooderham M, Chaudhry S, Fanton C, Yu D, Levy J, Liu Y, Miyazaki T, Tagliaferri M, Schmitz C, Nirula A, Kotzin B, Zalevsky J. Silverberg JI, et al. Nat Commun. 2024 Oct 25;15(1):9230. doi: 10.1038/s41467-024-53384-1. Nat Commun. 2024. PMID: 39455575 Free PMC article. Clinical Trial.
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).
Silverberg JI, Bunick CG, Hong HC, Mendes-Bastos P, Stein Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K. Silverberg JI, et al. Br J Dermatol. 2024 Dec 23;192(1):36-45. doi: 10.1093/bjd/ljae404. Br J Dermatol. 2024. PMID: 39438067 Clinical Trial.
704 results